U.S. FDA Panel Recommends Sanofi Dengue Vaccine Only For People Ages 9 Up To 17
STAT: Sanofi suffers setback as panel recommends against dengue vaccine in adults
“Sanofi on Thursday suffered a major setback in its bid to market a controversial dengue vaccine in the United States, as a Food and Drug Administration advisory committee recommended against approval for adults. … [T]he advisory panel recommended the agency license the vaccine only for people ages 9 to less than 17…” (Branswell, 3/7).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.